Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Four drugmakers work on Crestor & Zetia combo
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : May 28, 2014 04:10:14
Hanmi, Dream Pharma, Daewon and Nevipharm are conducting clinical trials of their combination drug of rosuvastatin (Crestor) and ezetimibe (Zetia), sources said on May 22.

Hanmi is the only one who does the trial by itself. Dream Pharma is cooperating with five companies, Daewon with four, and Nevipharm with five.

Hanmi and Dream Pharma entered the phase III clinical trial and the others will sooner or later.

As they want their combo drug to be approved as the first-line therapy for hypercholesterolemia, the cost is expected to reach a couple of billion won.

A pharmaceutical marketer said, “We will prove the effectiveness of the combo drug on LDL cholesterol levels, compared to a single agent. If the trial is completed as scheduled and the new combo drug is rolled out in 2016, it can be a blockbuster drug.”
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com